NeoGraph Analytics
PharmaceuticalsNorth America20232032

Pharmaceutical Testing Services Market Size, Share and Trends Analysis

Global pharmaceutical testing services market size reached $20.5B in 2023, projected to grow at 6.5% CAGR to $35.0B by 2032. Key drivers: regulatory complexity, biologics demand, AI adoption.

Revenue, 2023

$20.5B

Forecast, 2032

$35.0B

CAGR, 2024-2032

6.5%

Report Coverage

North America

Code: pharmaceutical-testing-services-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Market Overview

The pharmaceutical testing services market is experiencing sustained growth driven by regulatory complexity, rising drug development costs, and increasing demand for precision medicine, with a projected value of $35.0 billion by 2032 at a 6.5% CAGR.

Market Stage

High growth

Adoption Level

Growing

Key Trends

AI integration in data analysisRise of decentralized clinical trialsFocus on biologics and cell therapy testingConsolidation among CROs
02

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 6.5%

Base Year (2023)

$21.8B

Forecast (2032)

$35.0B

CAGR (2024-2032)

6.5%

Regional Market Analysis
Market share and growth rate by region

North America

#1
Share: 45.0%CAGR: 5.2%

Largest market: United States

Europe

#2
Share: 30.0%CAGR: 6.0%

Largest market: Germany

03

Market Dynamics

  • Increasing complexity of novel drug modalities
  • Stringent regulatory requirements globally
  • Rising drug development costs
  • Growth in biologics and gene therapies
04

Market Segmentation

By Application

  • Small Molecules
  • Biologics
  • Cell and Gene Therapies
  • Nanomedicines

By End User

  • Pharmaceutical Companies
  • Biotechnology Firms
  • Contract Research Organizations
  • Academic Institutions
05

Regional Analysis

1

North America

Lead: United States
CAGR: 5.2%Share: 45.0%

Dominates the market with advanced infrastructure and high R&D spending, accounting for nearly 80% of regional share.

2

Europe

Lead: Germany
CAGR: 6.0%Share: 30.0%

Strong regulatory framework and established CRO presence drive steady growth, particularly in biologics testing.

3

Asia Pacific

Lead: China
CAGR: 8.3%Share: 25.0%

Fastest-growing region due to manufacturing expansion, cost advantages, and increasing investment in R&D infrastructure.

Country-Level Analysis

CountryShareGrowth
United States
35.0%
+5.5%
Germany
12.0%
+6.1%
China
18.0%
+8.7%
06

Competitive Landscape

L

LabCorp

United States

Leader30.5B

Global leader in clinical testing with integrated R&D services, strong focus on AI-driven data analytics for trial optimization.

AI-Powered Clinical Trial AnalyticsPredictive Drug Safety Models
C

Charles River Laboratories

United States

Leader7.2B

Dominant in preclinical services with extensive animal model expertise and regulatory compliance support.

Bioanalytical AI PlatformToxicology Prediction Models
I

IQVIA

United States

Challenger

Leading provider of clinical trial management and real-world evidence solutions with strong digital health integration.

W

WuXi AppTec

China

Challenger12.8B

Major player in Asia-Pacific with end-to-end testing services for biologics and cell therapies.

AI-Driven Drug Discovery PlatformCell Therapy Testing Solutions
S

Syneos Health

United States

Challenger

Specializes in integrated clinical development services with focus on decentralized trials and AI implementation.

T

Thermo Fisher Scientific

United States

Follower

Strong in analytical instrumentation and reagent supply with growing testing services portfolio.

07

Recent Developments

25
2025LabCorp

Launched AI-integrated platform for real-time monitoring of clinical trial data, reducing analysis time by 40%.

25
2025Thermo Fisher Scientific

Introduced next-generation mass spectrometry systems for high-throughput biologics characterization.

24
2024WuXi AppTec

Expanded cell therapy testing capabilities through acquisition of a European CRO specializing in viral vector analysis.

24
2024Charles River Laboratories

Partnered with a major pharma company to develop organ-on-chip models for reduced animal testing.

24
2024IQVIA

Integrated blockchain technology for secure patient data sharing in decentralized clinical trials.

08

Regulatory Landscape

FDA's 2023 Guidance on AI in Clinical TrialsICH Q2(R2) Harmonized Analytical Validation GuidelinesEU MDR 2023 Updates for Medical Device TestingEMA's Revised Guidelines for Gene Therapy Testing
09

Frequently Asked Questions

The market size was $20.5 billion in 2023 and is projected to reach $35.0 billion by 2032.
The market is expected to grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2032.
North America holds the largest market share at 45.0%, led by the United States.
Primary drivers include increasing complexity of novel drug modalities, stringent global regulatory requirements, and rising drug development costs.